According to Anavex Life Sciences 's latest financial reports the company's current earnings (TTM) are -$46.94 M. an increase over its 2022 earnings that were of -$54.45 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 | -$46.94 M | -13.79% |
2022 | -$54.45 M | 22.96% |
2021 | -$44.28 M | 35.36% |
2020 | -$32.71 M | 12.65% |
2019 | -$29.04 M | 29.09% |
2018 | -$22.5 M | 36.33% |
2017 | -$16.5 M | 17.11% |
2016 | -$14.09 M | 20.91% |
2015 | -$11.66 M | -6.29% |
2014 | -$12.44 M | 337.28% |
2013 | -$2.85 M | |
2008 | -$5.26 M | 106.01% |
2007 | -$2.56 M | 8848.98% |
2006 | -$0.03 M | -79.99% |
2005 | -$0.15 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Ligand Pharmaceuticals LGND | $64.31 M | -237.04% | ๐บ๐ธ USA |
Corcept Therapeutics
CORT | $0.10 B | -328.59% | ๐บ๐ธ USA |
Palatin Technologies PTN | -$31.58 M | -32.72% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | -$0.23 B | 382.04% | ๐บ๐ธ USA |